Last reviewed · How we verify
BCD-131 (pegdarbepoetin beta)
BCD-131 is a pegylated erythropoiesis-stimulating agent that binds to and activates the erythropoietin receptor to stimulate red blood cell production.
BCD-131 is a pegylated erythropoiesis-stimulating agent that binds to and activates the erythropoietin receptor to stimulate red blood cell production. Used for Anemia associated with chronic kidney disease, Chemotherapy-induced anemia.
At a glance
| Generic name | BCD-131 (pegdarbepoetin beta) |
|---|---|
| Sponsor | Biocad |
| Drug class | Erythropoiesis-stimulating agent (ESA) |
| Target | Erythropoietin receptor (EPOR) |
| Modality | Biologic |
| Therapeutic area | Hematology/Oncology |
| Phase | Phase 3 |
Mechanism of action
As a pegylated darbepoetin beta analog, BCD-131 mimics endogenous erythropoietin by binding to EPO receptors on erythroid progenitor cells in the bone marrow, promoting their proliferation and differentiation into mature red blood cells. The pegylation extends the drug's half-life, allowing for less frequent dosing compared to shorter-acting erythropoiesis-stimulating agents. This mechanism is used to treat anemia associated with chronic kidney disease and chemotherapy.
Approved indications
- Anemia associated with chronic kidney disease
- Chemotherapy-induced anemia
Common side effects
- Hypertension
- Thromboembolism
- Headache
- Injection site reactions
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BCD-131 (pegdarbepoetin beta) CI brief — competitive landscape report
- BCD-131 (pegdarbepoetin beta) updates RSS · CI watch RSS
- Biocad portfolio CI